In summary, LOXL1-AS1 up-regulated in RCC accelerated the malignant behaviors of RCC cells through regulating miR-589-5p/CBX5 pathway, which may offer useful theoretical basis for exploring the new effective therapeutic strategies for patients RCC. Here, LOXL1 is linked to renal cell carcinoma.